期刊文献+

三种低分子肝素钙治疗不稳定性心绞痛的药物经济学分析 被引量:2

Pharmacoeconomic Analysis of Low Molecular Heparin in the Treatment of UAP
下载PDF
导出
摘要 目的:探讨三种低分子肝素钙治疗不稳定性心绞痛的经济效果。方法:应用药物经济学的成本-效果分析方法,对三种不稳定性心绞痛治疗方案的疗效进行回顾性分析评价。结果:方案C组为最佳方案。结论:通过分析,说明药物经济学的成本-效果分析方法在优化治疗方案,指导合理用药,提高经济效益方面具有重要作用。 Objective: To investigate the economics consequences of low molecular heparin in the treatment of UAP. Method: A retrospective analysis of three treatment projects of UAP was made by using the cost-effectiveness analysis. Result: Group C was the best project. Conclusion: The pharmacoeconomics analysis plays an important role in optimizing treatment projects and enhancing economic returns.
出处 《药物流行病学杂志》 CAS 2005年第5期295-297,共3页 Chinese Journal of Pharmacoepidemiology
关键词 药物经济学 成本-效果分析 不稳定性心绞痛 低分子肝素 Pharmacoeconomics Cost-effectiveness analysis UAP Low molecular heparin
  • 相关文献

参考文献5

二级参考文献11

  • 1[1]PatriciaAG, Kandice KM, Emilio DP, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease[J]. Am J Cardiol, 2001, 88:230 - 235
  • 2[2]Mehta SR. Aspirin and clopidogrel in patients with ACS undergoing PCI: CURE and PCI- CURE[J] .J Invasive Cardiol, 2003,15(Suppl B): 17B - 20B
  • 3[3]Simoons ML. Effect of glycoprotein Ⅱ b/Ⅲ a receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV- ACS randomised trial[J].Lancet, 2001, 357(9272): 1915 - 1924
  • 4[4]De Lemos JA, Antman EM, Gibson CM, et al. Abciximab improves both epicardial flow and myocardial reperfusion in ST- elevation myocardial infarction.Observations from the TIMI 14 trial[J]. Circulation,2000, 101(3) :239 - 243
  • 5[5]Topol EJ. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein Ⅱ b/Ⅲa inhibition: the GUSTO V randomised trial[J]. Lancet, 2001, 357(9272) :1905 - 1914
  • 6[6]Wallentin L, Goldstein P, Armstrong PW, et al. Efficacy and safety of tenecteplase in combination with the low - molecular- weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT) - 3 PLUS randomized trial in acute myocardial infarction [J ]. Circulation, 2003, 108(2): 135 - 142
  • 7[7]Antman EM, Louwerenburg HW, Baars HF, et al. Enoxaparin as adjunctive antithrombin therapy for STelevation myocardial infarction: results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23Trial[J]. Circulation, 2002, 105(14): 1642 - 1649
  • 8[8]Simoons M, Krzeminska - Pakula M, Alonso A, et al.Improved reperfusion and clinical outcome with enoxaparin as an adjunct to streptokinase thrombolysis in acute myocardial infarction. The AMI- SK study[J].Eur Heart J, 2002, 23 (16) :1282 - 1290
  • 9陈纪林.进一步提高对不稳定心绞痛的认识[J].中华心血管病杂志,1997,25:328-328.
  • 10陈水.低分子肝素治疗不稳定心绞痛疗效观察[J].镇江医学院学报,2000,10(4):739-740. 被引量:2

共引文献2718

同被引文献24

引证文献2

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部